Skip to content
yes i take peptides.
Library/For Recovery/BPC-157
RUO · Research Use Only⚠ Cancer Concern+2 more★ Popular

BPC-157

Body Protection Compound, 15 amino acids, isolated from human gastric juice. We read all 60 studies. The protocol is below.

Updated 19 May 2026Read 13 minEvidence ●○○○○Citations 60
+ Add to Stack
⚖ Compare side-by-side⎙ Print companion card

Free — puts BPC-157 on your decision board.

The BPC-157 Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status
Research-only
Class
Cancer Concern
Evidence
1/ 5●○○○○
Randomized human trials
$19 ↓
Phase 2 completed
$19 ↓
Case reports / off-label
$19 ↓
⚠ Cancer Concern
Read this if
  • you tore something and your PT said "give it 6 weeks" and you don't have 6 weeks
  • you've seen lifters on TikTok talking about it and want to know if it's real
  • you're recovering from surgery and your gym friend mentioned it
  • your dog's vet recommended it and you got curious for yourself
Skip this if
  • you want FDA-approved medication — this is research-only territory
  • you have an active or recent cancer history — the angiogenesis mechanism is the unanswered question
  • you're not comfortable with a research-grade supply chain and daily subcutaneous injections
The 4 ways you can buy BPC-157
Brand
✗
Not available
No FDA-approved BPC-157 exists; no realistic approval path.
Compounded 503A
⚠
Rx
$150–$400/mo where still sold
Some compounders ship under contested legal interpretations; pharmacies still selling are legally …
RUO (research-only)
✓
Sold 'for research only'
$50–$150/mo
The dominant supply by volume; identity by mass spec is the only honest check.
Gray market
✓
Unregulated overseas import
$10–$20/mo
Cheapest path; vendor variance is huge and 'buffered' upsells are common. Minimum order is one box.
Click any lane for the full Sourcing breakdown.
First 90 days · BPC-157
Weeks 1–2
Nothing perceptible. The healing-acceleration effect — if it's going to work — isn't a week-one signal. If you 'feel something' immediately, that's expectation, not the peptide.
Weeks 4–8
Subtle improvement on the target injury if it's going to work. Range of motion, less morning stiffness, less acute pain on load.
Week 12 — decide
Honest decision point. Either the injury is materially better than the no-peptide trajectory would have been, or it isn't. The clinical literature in humans is thin enough that your n=1 trial IS the evidence base.
Quit if
  • Any unusual symptoms — especially relevant if you have a personal or family cancer history (angiogenesis mechanism for BPC-157, TB-500).
  • 12 weeks with no perceived improvement vs the no-peptide trajectory.
  • New pain or symptoms at injection site that don't resolve in 48 hours.
Identity

What it is.

BPC stands for "Body Protection Compound." It's a partial sequence of a larger protein found naturally in human gastric juice, isolated by a Croatian research group led by Predrag Sikiric in the 1990s. The "157" refers to the specific 15-amino-acid fragment they synthesized.

Almost every published BPC-157 paper traces back to that same lab. This is a yellow flag. Independent replication is what separates a real signal from a researcher's lifelong project. We're still waiting for that replication outside Croatia.

The molecule itself is small enough to be made cheaply by a -synthesis pharmacy. It's sold as a research chemical () in the US — meaning it can be sold legally for research purposes but cannot be marketed for human use. Read about RUO sourcing.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what BPC-157 actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓
Mechanism

Mechanism.

Mechanism · in the BPC-157 report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓
Evidence

Evidence. What we actually know in humans.

Evidence · in the BPC-157 report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓
Human-Evidence Factbox
Randomized human trials
$19 ↓
Phase 2 completed
$19 ↓
Case reports / off-label
$19 ↓
Animal studies (mostly rat)
$19 ↓
Years of off-label use
$19 ↓
Community dose math (5mg vial)
$19 ↓
Injection site (community)
$19 ↓
Oral bioavailability
$19 ↓
Stack with TB-500
$19 ↓
Major adverse events flagged
$19 ↓
Dose

Dose. The actual protocol.

Dose · in the BPC-157 report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.
Get the report · $19 ↓
Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the BPC-157 report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.
Get the report · $19 ↓
Safety

Safety. Side effects.

Safety · in the BPC-157 report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓
Editorial Position

Editorial position.

Editorial Position · in the BPC-157 report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓
Citations

Citations.

  1. 01Józwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland). 2025;18(2). PMID: 40005999.
  2. 02Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and tissue research. 2019;377(2):153-159. PMID: 30915550.
  3. 03Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2025;21(4):15563316251355551. PMID: 40756949.
  4. 04Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology. 2021;12:627533. PMID: 34267654.
  5. 05Lee E, et al. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative therapies in health and medicine. 2021;27(4):8-13. PMID: 34324435.
+Show all 60 citations
  1. 06Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current pharmaceutical design. 2018;24(18):1972-1989. PMID: 29998800.
  2. 07Vukojevic J, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural regeneration research. 2022;17(3):482-487. PMID: 34380875.
  3. 08Park JM, et al. BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Current pharmaceutical design. 2020;26(25):2971-2981. PMID: 32445447.
  4. 09McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine. 2025;18(12):611-619. PMID: 40789979.
  5. 10Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985). 2011;110(3):774-80. PMID: 21030672.
  6. 11Staresinic M, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022;10(12). PMID: 36551977.
  7. 12Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157-Possible Novel Therapy of Glaucoma and Other Ocular Conditions. Pharmaceuticals (Basel, Switzerland). 2023;16(7). PMID: 37513963.
  8. 13Sikiric P, et al. Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. Current pharmaceutical design. 2020;26(25):2991-3000. PMID: 32329684.
  9. 14Seiwerth S, et al. BPC 157 and blood vessels. Current pharmaceutical design. 2014;20(7):1121-5. PMID: 23782145.
  10. 15Sikiric P, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel, Switzerland). 2024;17(4). PMID: 38675421.
  11. 16Lee E, et al. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative therapies in health and medicine. 2024;30(10):12-17. PMID: 39325560.
  12. 17Bajramagic S, et al. Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel, Switzerland). 2024;17(8). PMID: 39204186.
  13. 18Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. Pharmaceuticals (Basel, Switzerland). 2025;18(6). PMID: 40573323.
  14. 19Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function. Pharmaceuticals (Basel, Switzerland). 2023;16(5). PMID: 37242459.
  15. 20Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways. Current medicinal chemistry. 2023;30(13):1568-1573. PMID: 36200148.
  16. 21Deek SA. BPC 157 as Potential Treatment for COVID-19. Medical hypotheses. 2021;158:110736. PMID: 34798584.
  17. 22Sikiric P, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Current pharmaceutical design. 2014;20(7):1126-35. PMID: 23755725.
  18. 23Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and liver. 2020;14(2):153-167. PMID: 31158953.
  19. 24Sikiric P, et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World journal of gastroenterology. 2022;28(1):23-46. PMID: 35125818.
  20. 25Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation. Biomedicines. 2022;10(11). PMID: 36359218.
  21. 26Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current pharmaceutical design. 2011;17(16):1612-32. PMID: 21548867.
  22. 27Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current neuropharmacology. 2016;14(8):857-865. PMID: 27138887.
  23. 28Sikiric P, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current pharmaceutical design. 2013;19(1):76-83. PMID: 22950504.
  24. 29Sikiric P, et al. Acute Compartment Syndrome and Intra-Abdominal Hypertension, Decompression, Current Pharmacotherapy, and Stable Gastric Pentadecapeptide BPC 157 Solution. Pharmaceuticals (Basel, Switzerland). 2025;18(6). PMID: 40573261.
  25. 30Sikiric P, et al. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Current pharmaceutical design. 2018;24(18):1990-2001. PMID: 29879879.
  26. 31Whitehouse M. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT). Inflammopharmacology. 2025;33(8):4879-4881. PMID: 40759852.
  27. 32Zemba Cilic A, et al. BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling "Negative-Like" Symptoms of Schizophrenia. Biomedicines. 2022;10(7). PMID: 35884767.
  28. 33DeFoor MT, et al. Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2025;41(2):150-152. PMID: 39265666.
  29. 34Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026;10(1). PMID: 41490200.
  30. 35Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine. 2026;54(1):223-229. PMID: 41476424.
  31. 36Kralj T, et al. Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma. Biomedicines. 2021;10(1). PMID: 35052769.
  32. 37Jung YH, et al. The anti-nociceptive effect of BPC-157 on the incisional pain model in rats. Journal of dental anesthesia and pain medicine. 2022;22(2):97-105. PMID: 35449779.
  33. 38Seiwerth S, et al. BPC 157's effect on healing. Journal of physiology, Paris. 1997;91(3-5):173-8. PMID: 9403790.
  34. 39Gojkovic S, et al. BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment. Biomedicines. 2021;9(7). PMID: 34203464.
  35. 40Yuan C, et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences. 2026;27(6). PMID: 41898733.
  36. 41Zemba Cilic A, et al. Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia. Behavioural brain research. 2021;396:112919. PMID: 32956773.
  37. 42Matek D, et al. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1). PMID: 39861766.
  38. 43Masnec S, et al. Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy. Pharmaceuticals (Basel, Switzerland). 2025;18(12). PMID: 41471311.
  39. 44Kolovrat M, et al. Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion. World journal of hepatology. 2020;12(5):184-206. PMID: 32547687.
  40. 45Vukojević J, et al. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain and behavior. 2020;10(8):e01726. PMID: 32558293.
  41. 46Zlatar M, et al. BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats. Frontiers in pharmacology. 2021;12:632295. PMID: 34177567.
  42. 47Tepes M, et al. Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats. Pharmaceuticals (Basel, Switzerland). 2023;16(11). PMID: 38004420.
  43. 48Sikiric P, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185. Pharmaceuticals (Basel, Switzerland). 2025;18(10). PMID: 41155565.
  44. 49Smoday IM, et al. Pentadecapeptide BPC 157 as Therapy for Inferior Caval Vein Embolization: Recovery of Sodium Laurate-Post-Embolization Syndrome in Rats. Pharmaceuticals (Basel, Switzerland). 2023;16(10). PMID: 37895979.
  45. 50Barisic I, et al. Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats. Biomedicines. 2022;10(2). PMID: 35203478.
  46. 51Sikiric P, et al. Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?. Current pharmaceutical design. 2017;23(27):4012-4028. PMID: 28228068.
  47. 52Demirtaş H, et al. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas, Lithuania). 2025;61(2). PMID: 40005408.
  48. 53Sikiric P, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Current medicinal chemistry. 2012;19(1):126-32. PMID: 22300085.
  49. 54Lee E, et al. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative therapies in health and medicine. 2025;31(5):20-24. PMID: 40131143.
  50. 55Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5-6):214-21. PMID: 17186181.
  51. 56Vukusic D, et al. Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2024;75(1). PMID: 38583442.
  52. 57Stambolija V, et al. BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias. European journal of pharmacology. 2016;781:83-91. PMID: 27060013.
  53. 58Huang BS, et al. Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro. Life sciences. 2022;310:121072. PMID: 36228773.
  54. 59Japjec M, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines. 2021;9(11). PMID: 34829776.
  55. 60Tepes M, et al. Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats. Frontiers in pharmacology. 2021;12:718147. PMID: 34966273.
The BPC-157 Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.
Compare tiers →